A call for disruption and innovation in retail Rx

In preparing for the National Association of Chain Drug Stores Annual Meeting this year, I find myself thinking about the myriad opportunities reshaping retail pharmacy, including overcoming declining margins, winning expansion of pharmacist provider status, and leaning into consumer needs and value-based care. As I do so, I keep coming back to the guiding principle that we have been entrusted by our investors to create value by delivering patient safety, access and affordability in health care.

• Read more about A call for disruption and innovation in retail Rx

Leveraging Returns And Sustainability To Improve The Customer Experience

By Thomas Borders, VP and GM of Product Lifecycle Solutions: E-commerce continues to present merchants with new challenges and opportunities. Understanding the best way to address these challenges will boost shopper loyalty, increase customer lifetime value, and make your operations more sustainable.

• Read more about Leveraging Returns And Sustainability To Improve The Customer Experience

Inmar Intelligence Hosts 8th Medication Disposal Drive-Thru Event on April 27th

Safely dispose of unused or expired medications at Bolton Elementary School in Winston-Salem.

• Read more about Inmar Intelligence Hosts 8th Medication Disposal Drive-Thru Event on April 27th

Understanding DSCSA: Insights for All Dispensers

The article discusses how the DSCSA impacts medication dispensers, emphasizing compliance to protect patient safety and maintain supply chain integrity. It covers pharmaceutical crime, counterfeit drug risks, key DSCSA measures like product serialization, and stresses technology's role in ensuring authenticity. Compliance with regulations is crucial for a secure healthcare environment.

• Read more about Understanding DSCSA: Insights for All Dispensers

DIR reform in 2024: One step forward, two steps back

The article delves into the advancements and obstacles facing Direct and Indirect Remuneration (DIR) reform in 2024 within the pharmacy sector. It outlines the move from retroactive to upfront DIR fees, the financial pressures on pharmacies, and initiatives to broaden the scope of pharmacy services. Despite certain improvements like clawback elimination, the transition has introduced cash flow difficulties and decreased transparency. The article underscores the significance of comprehending and managing these reforms to bolster pharmacy viability and promote value-based care endeavors.

• Read more about DIR reform in 2024: One step forward, two steps back

Manufacturer CMOs Reevaluate Retail Media Network Investments

Inmar Intelligence Research Reveals Future Outlook of the State of Retail Media Networks

• Read more about Manufacturer CMOs Reevaluate Retail Media Network Investments

Successful Returns Management Starts With An Effective Returns Policy

Establishing a clear and consistent returns policy is an absolute requirement for any drug- or device-maker committed to successfully mitigating the financial liability attached to product flowing back through the supply chain.

• Read more about Successful Returns Management Starts With An Effective Returns Policy

US Department of Health and Human Services Selects Inmar Intelligence for a 5-year Contract to Deliver Pharmaceutical Supply Chain Solutions

Inmar Intelligence, a leading provider of data-driven healthcare technology solutions, today announced it has secured a contract with the US Department of Health and Human Services (HHS) to provide pharmaceutical supply chain solutions across the country.

• Read more about US Department of Health and Human Services Selects Inmar Intelligence for a 5-year Contract to Deliver Pharmaceutical Supply Chain Solutions

Importing Drugs from Canada: Prudent policy or political ploy?

The recent decision by the Food and Drug Administration to approve Florida’s Canadian Prescription Drug Importation Program was definitely a new development in the “Will Canadian drug imports solve anything?” saga, but that the FDA gave the state the go-ahead should be no real surprise to anyone.

• Read more about Importing Drugs from Canada: Prudent policy or political ploy?